Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Canagliflozin Alters Mitochondrial Structure in Diabetic Kid
2026-05-21
This study demonstrates that canagliflozin, an SGLT2 inhibitor, promotes structural and functional improvements in proximal tubular cell mitochondria in hypertensive–diabetic mice. These findings suggest that mitochondrial remodeling may underlie the nephroprotective effects of SGLT2 inhibition, with implications for diabetes and kidney disease research.
-
Dehydroabietic Acid: Advanced Modulation of PPAR-α/γ in Meta
2026-05-20
Explore how Dehydroabietic acid, a dual PPAR-α/γ agonist, enables advanced, mechanism-driven metabolic disorder research. This article reveals deeper scientific insights and recent reference findings that expand practical workflows beyond established protocols.
-
Sitagliptin Phosphate Monohydrate: Protocols and Troubleshoo
2026-05-20
Sitagliptin phosphate monohydrate empowers metabolic researchers with precision DPP-4 inhibition and reproducible incretin hormone modulation. This guide details workflow enhancements, protocol parameters, and troubleshooting strategies to maximize experimental success in type II diabetes and metabolic disease models.
-
(+)-Bicuculline: Practical Guide to GABAA Receptor Antagonis
2026-05-19
(+)-Bicuculline provides a means to selectively antagonize GABAA receptors and dissect inhibitory neurotransmission in neuroscience research. This compound is not suitable for diagnostic or clinical use and demands precise handling for reproducible results.
-
Trelagliptin Succinate in Diabetes Research: Applied Protoco
2026-05-19
Trelagliptin succinate (SYR-472 succinate) offers unique workflow advantages for diabetes mellitus research, enabling once-weekly, long-acting DPP-4 inhibition. This article distills validated experimental protocols, novel cognitive endpoints, and troubleshooting strategies to maximize data quality across metabolic and inflammation models.
-
Single-Base 5hmC Mapping Illuminates Rice Drought Epigenetic
2026-05-18
This study delivers the first single-base resolution map of 5-hydroxymethylcytosine (5hmC) in rice, revealing how its genomic distribution and dynamic interplay with 5-methylcytosine (5mC) regulate gene expression during drought. The findings establish 5hmC as a context-dependent epigenetic mark, advancing research on plant stress adaptation and crop resilience.
-
Enhanced mTOR Inhibitor Detection Using Drug-Sensitized Yeas
2026-05-18
Breen et al. introduce a yeast-based system with heightened sensitivity for identifying mechanistic target of rapamycin (mTOR) inhibitors, addressing the limitations of rapamycin and its analogs. This platform accelerates discovery of compounds with geroprotective and anti-cancer potential, and provides a robust negative control framework for non-TOR-targeted agents.
-
A Drug-Sensitized Yeast Platform for mTOR Inhibitor Discover
2026-05-17
Breen et al. (2025) introduce a novel yeast-based assay system that dramatically increases sensitivity for detecting mTOR pathway inhibitors, facilitating rapid small-molecule screening. Their work clarifies that compounds like Canagliflozin do not cross-inhibit the mTOR pathway, guiding researchers toward more targeted, pathway-specific studies.
-
Trelagliptin Succinate: Multidimensional Mechanisms in Diabe
2026-05-16
Explore the advanced biology of Trelagliptin succinate—a long-acting, selective DPP-4 inhibitor powering diabetes mellitus research and novel anti-inflammatory applications. Discover unique mechanistic insights and protocol strategies that set this compound apart.
-
Anagliptin (SK-0403): DPP-4 Inhibition Meets Vascular Ion Ch
2026-05-15
Discover how Anagliptin (SK-0403) uniquely integrates DPP-4 inhibition with direct modulation of Kv channels and SERCA pumps, advancing research in diabetes and vascular physiology. This article uncovers the nuanced mechanisms and practical assay implications that set Anagliptin apart.
-
Trelagliptin succinate (SKU A3889): Optimizing Diabetes Rese
2026-05-15
Explore how 'Trelagliptin succinate' (SKU A3889) addresses real-world laboratory challenges in diabetes mellitus research. This evidence-based article guides researchers through protocol optimization, assay compatibility, and data interpretation, emphasizing reproducibility, reliability, and validated best practices with direct links to protocols and supplier resources.
-
Trelagliptin Succinate Restores Chondrocyte Function via AMP
2026-05-14
The referenced study demonstrates that trelagliptin succinate, a selective DPP-4 inhibitor, significantly counteracts IL-1β-induced dysfunction in human chondrocytes by activating the AMPK/SOX-9 pathway. These findings introduce a novel anti-inflammatory mechanism for a compound primarily used in type 2 diabetes research, with implications for osteoarthritis and metabolic disease comorbidity studies.
-
Anagliptin (SK-0403): Applied DPP-4 Inhibition in Vascular R
2026-05-14
Unlock the dual power of Anagliptin (SK-0403) for both metabolic and vascular research: its ability to induce vasorelaxation via Kv channel and SERCA pump activation offers unique insight beyond glycemic control. This guide delivers protocol detail, troubleshooting, and advanced workflow strategies grounded in recent experimental breakthroughs.
-
Triptolide (PG490): Precision Tool for Cancer and Immunology
2026-05-13
Triptolide (PG490) delivers nanomolar-potency inhibition of key inflammatory and cancer signaling pathways, enabling robust, reproducible research in oncology and immunology. This guide synthesizes experimental workflows and troubleshooting strategies—leveraging APExBIO’s validated Triptolide—for researchers seeking superior data clarity in cell-based and in vivo disease models.
-
Cyclic di-GMP: Protocols for Biofilm & Immune Modulation Res
2026-05-13
Cyclic di-GMP stands at the crossroads of bacterial persistence and immune signaling, unlocking new workflows in both biofilm biology and cancer immunotherapy studies. This article delivers stepwise protocols, troubleshooting insights, and actionable context from the latest research, equipping scientists to harness this potent intracellular second messenger for advanced applications.